The "la Caixa" Foundation, through its 2026 CaixaImpulse Health Innovation Call program, has allocated nearly 4 million euros to support 30 innovative health projects. Out of 449 proposals received, 23 new projects were selected, along with 7 initiatives advancing to a higher development phase. CaixaImpulse is consolidating its role as a key initiative for the transfer of biomedical innovation.
Among the projects selected for phase 3 is MEDAL, led by Dr. SERGIO SERRANO VILLAR, coordinator of Area 2 at IRYCIS. The project has secured €438,000 in funding, continuing a research line previously supported by the "la Caixa" Foundation in 2023. Anal cancer, caused by persistent human papillomavirus (HPV) infection, has an average annual incidence increase of approximately 2% and particularly affects high-risk populations such as people living with HIV.
MEDAL proposes an innovative, minimally invasive, and affordable diagnostic tool based on microbiome biomarkers to more accurately identify anal precancerous lesions (HSIL). The project is developing the MEDAL KIT, a device for routine clinical laboratories that uses Enzyme-Linked OligoNucleotide Assay (ELONA) technology with aptamers instead of antibodies, targeting cobalamin and succinyl-CoA, metabolites significantly elevated in individuals with anal precancerous lesions.
This new tool aims to reduce unnecessary invasive procedures, enhance the efficiency of screening programs, and contribute to lowering healthcare costs. Researchers will also explore the potential of these biomarkers for application in other epithelial cancers, such as cervical and colorectal cancer.
The MEDAL project is coordinated at IRYCIS by Dr. SERGIO SERRANO and involves a multidisciplinary team. Clinical participants include Dr. CLARA CRESPILLO and Dr. JAVIER MARTÍNEZ-SANZ from the Anal Dysplasia Unit, Dr. FRANCISCO CAMPILLO (CERVICAM program), Dr. BEATRIZ ROMERO, and Dr. JUAN CARLOS GALÁN from the Clinical Microbiology service. Experimental development is led by Dr. ELENA MORENO, with Dr. VÍCTOR M. GONZÁLEZ contributing expertise in aptamer identification and development. The team is completed by Dr. SARA SAIZ, responsible for project management and operational coordination, and Dr. EMMA GONZÁLEZ, head of IRYCIS's Innovation Unit.
The official award ceremony for the selected projects took place on October 15th at CosmoCaixa (Barcelona), attended by representatives from the 80 selected research, innovation, and health promotion projects. IRYCIS representatives were Dr. Serrano and Dr. Moreno. MEDAL's selection by the CaixaImpulse Call reinforces IRYCIS's leadership in developing innovative solutions for patient prevention, early diagnosis, and care.




